Nautilus Biotechnology Stock Today
| NAUT Stock | USD 0.99 0.01 1.00% |
PerformanceVery Weak
| Odds Of DistressAverage
|
Nautilus Biotechnology is selling for under 0.99 as of the 22nd of March 2025; that is 1 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 0.95. Nautilus Biotechnology has 51 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of June 2021 | Category Healthcare | Classification Health Care |
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company was founded in 2016 and is headquartered in Seattle, Washington. The company has 126.15 M outstanding shares of which 283.23 K shares are now shorted by private and institutional investors with about 2.88 trading days to cover. More on Nautilus Biotechnology
Moving together with Nautilus Stock
Moving against Nautilus Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Nautilus Stock Highlights
| Thematic Idea | Measuring and Control Equipment (View all Themes) | ||||
| Old Name | Nautilus Marine Services PLC | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Measuring and Control Equipment, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsNautilus Biotechnology can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Nautilus Biotechnology's financial leverage. It provides some insight into what part of Nautilus Biotechnology's total assets is financed by creditors.
| |||||
Nautilus Biotechnology (NAUT) is traded on NASDAQ Exchange in USA. It is located in 2701 Eastlake Avenue East, Seattle, WA, United States, 98102 and employs 155 people. Nautilus Biotechnology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 126.14 M. Nautilus Biotechnology conducts business under Biotechnology sector and is part of Health Care industry. The entity has 126.15 M outstanding shares of which 283.23 K shares are now shorted by private and institutional investors with about 2.88 trading days to cover.
Nautilus Biotechnology currently holds about 299.34 M in cash with (59.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Nautilus Biotechnology Probability Of Bankruptcy
Ownership AllocationNautilus Biotechnology maintains a total of 126.15 Million outstanding shares. Nautilus Biotechnology holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Nautilus Ownership Details
Nautilus Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Tikvah Management Llc | 2024-12-31 | 726.9 K | |
| Clarius Group, Llc | 2024-12-31 | 636.5 K | |
| Botty Investors Llc | 2024-12-31 | 606.1 K | |
| Northern Trust Corp | 2024-12-31 | 474.8 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 393.6 K | |
| Wexford Capital Lp | 2024-12-31 | 325.2 K | |
| Sentinel Trust Co Lba | 2024-12-31 | 255 K | |
| Alyeska Investment Group, L.p. | 2024-12-31 | 253.5 K | |
| Renaissance Technologies Corp | 2024-12-31 | 250.2 K | |
| Perceptive Advisors Llc | 2024-12-31 | 12.6 M | |
| Cercano Management Llc | 2024-12-31 | 7.2 M |
Nautilus Biotechnology Historical Income Statement
Nautilus Stock Against Markets
Nautilus Biotechnology Corporate Management
| Gwen Weld | Chief Officer | Profile | |
| Parag Mallick | Chief CoFounder | Profile | |
| Sujal Patel | CEO, CoFounder | Profile | |
| Mary Godwin | Senior Operations | Profile | |
| Chris Blessington | Vice Communications | Profile | |
| Subra Sankar | Senior Development | Profile | |
| Kentaro Suzuki | Chief Officer | Profile |
Additional Tools for Nautilus Stock Analysis
When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.